DSP Nifty Healthcare Index Fund
DSP Mutual FundIndex: Index FundsRegular planGrowth
Overview
NAV
₹11.1861
Gain 1.09% 1-day changeData as of 9 Oct 2026
- 1 year
- Gain 8.2%
- 3 years
- —
- 5 years
- —
The principal will be at Very High risk
Data as of 9 Oct 2026Source: amfiHow we calculatePast performance may or may not be sustained in future. Returns shown are not an indication of future returns.
Trailing returns
Periods under 1 year show absolute return. 1 year and longer show CAGR (annualised).
| Period | This fund | Nifty Healthcare TRI | Category average |
|---|---|---|---|
| 1 month | Loss 4.45% | Loss 4.38% | Loss 3.46% |
| 3 months | Loss 2.79% | Loss 2.62% | Loss 2.82% |
| 6 months | Gain 11.66% | Gain 12.17% | Gain 1.35% |
| 1 year | Gain 8.20% | Gain 9.18% | Loss 1.42% |
| 3 years | — | Gain 19.13% | Gain 8.83% |
| 5 years | — | Gain 12.78% | Gain 7.30% |
| 7 years | — | Gain 21.06% | Gain 12.14% |
| 10 years | — | Gain 10.42% | Gain 10.48% |
| Since launch | Gain 8.96% | Gain 14.63% | Gain 5.41% |
SIP returns (XIRR)
XIRR of a monthly SIP over each period, valued at the latest NAV.
| Period | This fund | Nifty Healthcare TRI | Category average |
|---|---|---|---|
| 1 year | Gain 8.42% | Gain 9.38% | Loss 3.35% |
| 3 years | — | Gain 11.51% | Gain 3.48% |
| 5 years | — | Gain 16.07% | Gain 6.67% |
| 10 years | — | Gain 15.23% | Gain 9.30% |
Calendar-year returns
Show as table
| Year | This fund | Nifty Healthcare TRI |
|---|---|---|
| 2026 (year to date) | ▲ +8.07% | ▲ +8.83% |
Past performance may or may not be sustained in future. Returns shown are not an indication of future returns.
Rolling returns
Returns over every possible holding period since launch show the range of outcomes an investor could have had, not just one start date.
| Holding period | 1Y |
|---|---|
| Lowest | 8.17% |
| Median | 12.04% |
| Average | 12.53% |
| Highest | 17.62% |
| Periods with a loss | 0.0% |
| Periods above 8% | 100.0% |
| Periods above 10% | 95.8% |
| Periods above 12% | 51.4% |
| Number of periods | 72 |
Distribution and comparison with the benchmark
Calculating…
Past performance may or may not be sustained in future. Returns shown are not an indication of future returns.
Risk measures (3 years)
Calculated on daily NAVs over the last 3 years. Tap ? for a plain-language explanation.
- Standard deviation
Standard deviation
How much the fund's returns swing around their average, per year. A higher number means a bumpier ride.
- Not available
- Sharpe ratio
Sharpe ratio
Return earned above a treasury-bill rate for each unit of ups and downs. Higher means more return for the risk taken.
- Not available
- Sortino ratio
Sortino ratio
Like the Sharpe ratio, but it counts only the falls, not the rises. Higher is better.
- Not available
- Beta
Beta
How much the fund tends to move when its benchmark moves. 1 means the same as the benchmark; below 1 means it moved less.
- Not available
- Alpha
Alpha
Return per year above what the fund's beta would predict from the benchmark. Positive means the fund added value.
- Not available
- Maximum drawdown
Maximum drawdown
The deepest fall from a peak to a later low. It shows the worst loss an investor would have seen on paper.
- Not available
- Up-market capture
Up-market capture
How much of the benchmark's gains the fund caught in rising months. Above 100% means it rose more.
- Not available
- Down-market capture
Down-market capture
How much of the benchmark's losses the fund took in falling months. Below 100% means it fell less.
- Not available
Fund facts
- Fund size (AUM)
- ₹24 Cr
- Expense ratio (TER)
- 1.08%
- Exit load
- Not available
- Minimum SIP
- Not available
- Minimum lumpsum
- ₹100
- Launch date
- 2 Jun 2025
- Fund managers
- Not available
- Benchmark index
- Nifty Healthcare TRI
- Category
- Index: Index Funds
- Fund house
- DSP Mutual Fund
- Scheme type
- Open Ended
- AMFI scheme code
- 153592
- ISIN
- INF740KA1WC7
Portfolio holdings
| Holding | Sector | Weight |
|---|---|---|
| Sun Pharmaceutical Industries LimitedPharmaceuticals & Biotechnology | Pharmaceuticals & Biotechnology | 17.01% |
| Divi's Laboratories LimitedPharmaceuticals & Biotechnology | Pharmaceuticals & Biotechnology | 10.44% |
| Apollo Hospitals Enterprise LimitedHealthcare Services | Healthcare Services | 7.43% |
| Laurus Labs LimitedPharmaceuticals & Biotechnology | Pharmaceuticals & Biotechnology | 6.82% |
| Cipla LimitedPharmaceuticals & Biotechnology | Pharmaceuticals & Biotechnology | 6.70% |
| Dr. Reddy's Laboratories LimitedPharmaceuticals & Biotechnology | Pharmaceuticals & Biotechnology | 6.65% |
| Torrent Pharmaceuticals LimitedPharmaceuticals & Biotechnology | Pharmaceuticals & Biotechnology | 6.25% |
| Max Healthcare Institute LimitedHealthcare Services | Healthcare Services | 6.12% |
| Lupin LimitedPharmaceuticals & Biotechnology | Pharmaceuticals & Biotechnology | 4.36% |
| Aurobindo Pharma LimitedPharmaceuticals & Biotechnology | Pharmaceuticals & Biotechnology | 4.09% |
| Fortis Healthcare LimitedHealthcare Services | Healthcare Services | 3.55% |
| Glenmark Pharmaceuticals LimitedPharmaceuticals & Biotechnology | Pharmaceuticals & Biotechnology | 3.11% |
| Alkem Laboratories LimitedPharmaceuticals & Biotechnology | Pharmaceuticals & Biotechnology | 2.75% |
| Zydus Lifesciences LimitedPharmaceuticals & Biotechnology | Pharmaceuticals & Biotechnology | 2.55% |
| Mankind Pharma LimitedPharmaceuticals & Biotechnology | Pharmaceuticals & Biotechnology | 2.51% |
Portfolio as of 30 Sept 2026 · top 15 of 22 holdings, 90.3% of the portfolio
Try this fund in our tools
See how a SIP, a lumpsum or withdrawals in this fund would have done, using its real NAV history.
Data sources
| Data | Source | As of |
|---|---|---|
| Latest NAV | amfi | 9 Oct 2026 |
| NAV history | captnemo | 9 Oct 2026 |
| Expense ratio | amfi | 9 Oct 2026 |
| Fund size | amfi | 8 Oct 2026 |
| Riskometer | amfi | 8 Oct 2026 |
| Scheme details | amfi | 9 Oct 2026 |
| Holdings | amc:dsp | 30 Sept 2026 |
| Benchmark | niftyindices | 9 Oct 2026 |
| minLumpsum | amfi | 9 Oct 2026 |
| launch | amfi | 9 Oct 2026 |
Mutual fund investments are subject to market risks, read all scheme related documents carefully.